Policy Cures News Today

Investment in research to tackle poverty-related and neglected diseases – such as TB and malaria – has fallen since the COVID-19 pandemic, according to Andrew Tuttle, chief strategy officer of Policy Cures Research.  After rising steadily, annual investment in such research began to plateau in 2018 and then declined in the wake of the pandemic, he told a session entitled Deepening cooperation with the Global South for sustainable health futures at the Science|Business Annual Conference, org...

Congressman Brian Fitzpatrick (PA-01), Congresswoman María Elvira Salazar (FL-27), and Congresswoman Chrissy Houlahan (PA-06) introduced the Supporting Innovative Global Health Technologies (SIGHT) Act of 2023, which would establish a disease-agnostic research and development program at the US Agency for International Development in the House of Representatives.

But dengue in wealthy countries could divert medication away from poorer nations that may need it more

Increased investment into previously neglected diseases could see poorer countries left behind.

Climate change and other environmental factors could cause Lassa fever to spread to additional regions within Africa, new research predicts. CEPI is the leading funder of research into vaccines against the potentially deadly virus.

ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero

In todays Research Roundup for January 31, 2022, we highlight some of the most interesting reads in global health research and development from the past week.

Is There a Third Way to Ensure Equitable Access to COVID-19 Vaccines for All Countries? The WTO heads “third way” proposal is likely to undermine efforts at the TRIPS Council seeking a temporary waiver of certain IP rules that would augment the manufacturing capacity of vaccines. A vial of the AstraZeneca coronavirus vaccine doses at a facility in Milton, Ontario, Canada March 3, 2021. Photo: Reuters/Carlos Osorio Trade06/Mar/2021 On March 1, Ngozi Okonjo-Iweala took over as Direct...